Overview

A Randomized, Placebo-Controlled, Double-Blind, Double Dummy Trial To Determine The Relative Effect Of Pm101 Versus Placebo And Amiodarone IV On Blood Pressure In Subjects With Stable Congestive Heart Failure

Status:
Withdrawn

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this trial is to compare the relative hemodynamic effect of a novel intravenous formulation of amiodarone (PM101), administered as an immediate IV bolus push, with placebo and with the currentlyl available formulation of Amiodarone IV, administered as a 10-minute IV infusion, on systolic arterial pressure.

Phase:

Phase 2

Details

Lead Sponsor:

Prism Pharmaceuticals

Treatments:

Amiodarone